Clean up clinical pipeline Roche calls off 6 clinical projects!

On April 22nd Roche reported first-quarter 2020 results of 15.1 billion Swiss francs, up 2% year-on-year, with sales in the pharmaceutical division up 7% to SFr12.3 billion.
, however, it is worth noting that Roche conducted a clinical "clean-up" in the first quarter, stopping six clinical projects, including two phase III clinical trials.
roche's two Phase 3 clinical projects, one of which is related to the research of the new oral drug balovaptan (RG7314), a pressurizin 1a (V1a) receptor antagonist that can be used to treat patients with autism spectrum disorder (ASD), and was certified by the FDA in January 2018 as a breakthrough therapy.
earlier, a study of adult men with autism showed that balovaptan showed therapeutic advantages in terms of social function scores, and higher doses of medication improved patient adaptive behavioral scores, but did not achieve statistically significant results.
Roche revealed that a balovaptan study of adults with autism stopped after a pre-planned ineffectiveness analysis in the first quarter of this year.
did not release details about the drug's future development.
in fact, the pharmaceutical industry as a whole has also experienced bottlenecks in the development of effective treatments for autism, with Novartis and Seaside Therapeutics canceling plans to develop drugs in addition to Roche. Another phase 3 clinical project that
Roche stopped involved MDM2 inhibitor idasanutlin (RG7388).
last September, Roche said it was conducting phase 3 clinical trials to test the efficacy of idasanutlin and cytarabine in the treatment of patients with recurrent/refractive acute myeloid leukemia, and was exploring the efficacy of the drug, which could be used in combination with other drugs to treat patients with different leukemias.
the original outside world had high expectations of the drug, did not expect to come from such a news.
, another phase 2 clinical phase of the drug for true erythrocyte hypertrophy was also cancelled.
Basmisanil (RG1662), a highly selective reverse agonist/negative-variable structure regulator with alpha3 subaseed receptor, was also discontinued, previously thought to have the potential to treat cognitive impairment associated with Down syndrome.
last September, Roche said it had completed Phase 1 clinical trials of Parkinson's therapy prasinezumab, which is working with Prothena, and the results of Phase 2 clinical trials are expected to be available in 2020.
the drug is a monoclonal antibody that targets synaptic nucleoprotein polymers, Roche added, adding that the Phase 2 clinical trial of prasinezumab did not meet its main objectives but showed signs of efficacy and is currently evaluating test data to determine the next steps in the drug trial.
Roche's trial also includes emolizumab, a monoclonal antibody that blocks the conduction of IL-31 signals and is being tested for itching and adhesion dermatitis in dialysis patients.
reference source: Roche culls key phase 3 drug trials, including a cancer med d'an autism 'othe' therapy.